BeOne Medicines(BEIGF)
CA - San Carlos
BiotechnologyFocus: Small Molecules, Monoclonal Antibodies
BeOne Medicines is a life sciences company focused on Small Molecules, Monoclonal Antibodies.
OncologyNephrologyImmunologyDermatology
Funding Stage
PUBLIC
Employees
12,000
Open Jobs
312
Products & Portfolio (1)
1 discontinued product not shown
Pipeline & Clinical Trials
Zanubrutinib
Waldenstrom MacroglobulinemiaClinical Trials (1)
NCT05640102Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
N/AZanubrutinib
Waldenström's MacroglobulinemiaClinical Trials (1)
NCT05326308Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
N/ABGB-45035
Healthy ParticipantsClinical Trials (1)
NCT06342713A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
Phase 1BGB-53038
Metastatic Solid TumorsClinical Trials (1)
NCT06585488A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Phase 1BGB-B2033
Metastatic Hepatocellular CarcinomaClinical Trials (1)
NCT06427941A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Phase 1BG-C0902
Solid TumorsClinical Trials (1)
NCT07181681A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Phase 1BGB-21447
Relapsed Non-Hodgkin LymphomaClinical Trials (1)
NCT05828589A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
Phase 1Phase 1
Clinical Trials (1)
NCT06756932BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Phase 1BGB-11417
Mature B-cell MalignanciesClinical Trials (1)
NCT04883957Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
Phase 1Drug: BG-T187
Advanced Solid TumorClinical Trials (1)
NCT06598800Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
Phase 1BGB-24714
Solid Tumor, AdultClinical Trials (1)
NCT05381909A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
Phase 1BGB-R046
Solid TumorClinical Trials (1)
NCT06487858A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
Phase 1BGB-B455
Advanced Solid TumorClinical Trials (1)
NCT06803680A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
Phase 1BGB-B3227
Advanced CancerClinical Trials (1)
NCT06540066A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
Phase 1BG-C0979
Advanced Solid TumorClinical Trials (1)
NCT07414836A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
Phase 1Lifirafenib
Solid Tumor, AdultBG-60366
Non-Small Cell Lung CancerClinical Trials (1)
NCT06685718A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Phase 1BGB-C354
Advanced Solid TumorClinical Trials (1)
NCT06422520A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT06568614An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors
Phase 1BG-68501
Breast CancerClinical Trials (1)
NCT06257264A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1Tarlatamab
Extensive Stage Small Cell Lung CancerBGB-58067
Advanced Solid TumorClinical Trials (1)
NCT06589596An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Phase 1BGB-16673
Chronic Spontaneous UrticariaClinical Trials (1)
NCT07005713A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria
Phase 1BG-A3004
Skin DiseasesClinical Trials (1)
NCT07412691A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases
Phase 1BGB-15025
Advanced Solid TumorClinical Trials (1)
NCT04649385BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
Phase 1BG-C477
Advanced Solid TumorsClinical Trials (1)
NCT06596473A Study of BG-C477 in Participants With Advanced Solid Tumors
Phase 1BGB-16673
Healthy VolunteersClinical Trials (1)
NCT06906809Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants
Phase 1BG-75098
Advanced Solid TumorClinical Trials (1)
NCT07226349A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Phase 1BG-71332
Healthy VolunteersClinical Trials (1)
NCT07141511A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults
Phase 1BG-75202
Breast CancerClinical Trials (1)
NCT07222267An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Phase 1BG-C137
Advanced Solid TumorClinical Trials (1)
NCT06625593A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
Phase 1BGB-26808
Advanced Solid TumorClinical Trials (1)
NCT05981703A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Phase 1BG-C9074
Advanced Solid TumorClinical Trials (1)
NCT06233942Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Phase 1BGB-43395
Advanced Solid TumorClinical Trials (1)
NCT06120283BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1BGB-10188
Chronic Lymphocytic LeukemiaClinical Trials (1)
NCT04282018Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
Phase 1/2BGB-A445
Urothelial CarcinomaClinical Trials (1)
NCT05661955A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
Phase 1/2Zanubrutinib
Mature B-cell MalignanciesClinical Trials (1)
NCT04172246Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
Phase 1/2BGB-11417
Acute Myeloid LeukemiaClinical Trials (1)
NCT04771130A Study of BGB-11417 in Participants With Myeloid Malignancies
Phase 1/2BGB-16673
B-cell MalignancyClinical Trials (1)
NCT06634589A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1/2BGB-16673
B-cell MalignancyClinical Trials (1)
NCT05006716A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Phase 1/2Sonrotoclax
Relapsed/Refractory Multiple MyelomaClinical Trials (1)
NCT04973605A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Phase 1/2Blinatumomab
B Cell Precursor Acute Lymphoblastic LeukemiaPhase 1/2
Sonrotoclax
Chronic Lymphocytic LeukemiaClinical Trials (1)
NCT06697184A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Phase 1/2Tislelizumab
Gastroesophageal AdenocarcinomaBiospecimen Collection
Recurrent Transformed Chronic Lymphocytic LeukemiaClinical Trials (1)
NCT05873712Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Phase 2Zanubrutinib
Mantle Cell LymphomaClinical Trials (1)
NCT07341191Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Phase 2Tislelizumab
MSI-H/dMMR Solid TumorsClinical Trials (1)
NCT03736889Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Phase 2Tislelizumab
Colorectal CancerClinical Trials (1)
NCT05116085Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer
Phase 2Tislelizumab
Non Small Cell Lung CancerClinical Trials (1)
NCT05577702Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
Phase 2Open Jobs (312)
Senior Director, ERP COE and Architecture
Remote
Yesterday
$207K - $277K/yr
Senior Manager, Oncology Program Management
Remote
Yesterday
$142K - $187K/yr
USMA Field Medical Excellence, Director
Remote
Yesterday
$192K - $252K/yr
Senior Manager, Digital Quality Management Systems, Business Analyst
Remote
Yesterday
$133K - $178K/yr
Senior Engineer I, Site Automation
Hopewell
Yesterday
$115K - $155K/yr
Senior Manager, Corporate Strategy
Remote
Yesterday
$135K - $180K/yr
Senior Study Start-Up Specialist
Remote
Yesterday
$84K - $114K/yr
Senior Manager, Consolidation Accounting
Warsaw
Yesterday
OTC EMEA and New Market Team Lead
Warsaw
Yesterday
OTC Specialist - AR
Warsaw
Yesterday
Business Operations Director
Remote
Yesterday
Account Manager - Solid Tumor
PA-Home Office, US
Yesterday
$159K - $204K/yr
Senior OTC Specialist – Credit Management
Warsaw
Yesterday
Market Access Manager
Milan
2d ago
Manager/Senior Manager, Regional Clinical Compliance, JAPAC
Seoul
2d ago
Senior Data Management Systems Admin
Remote
2d ago
$100K - $135K/yr
Manager, TMF Systems
Remote
2d ago
$124K - $164K/yr
Senior Medical Director-Biotech Unit
Remote
2d ago
$300K - $370K/yr
Senior Manager, Digital Quality Management Systems, Business Analyst
2d ago
Senior Manager, Clinical Science
Remote
3d ago
$142K - $187K/yr
Director CDx Development
Remote
3d ago
$177K - $237K/yr
Senior Manager, Clinical Business Development Insights
Remote
4d ago
$142K - $187K/yr
Associate Director, Platform Engineering - BioAgent
Remote
4d ago
$158K - $208K/yr
Associate Director, Oncology Program Management
Remote
4d ago
$149K - $199K/yr
Key Account Manager, Solid Tumours - North of England/Scotland, UK
Remote
5d ago
Interview Prep Quick Facts
Portfolio: 2 approved products, 56 clinical trials
Top TAs: Oncology, Nephrology
SEC Filings: 2 available
Open Roles: 312 active jobs
Portfolio Health
Launch1 (50%)
Peak1 (50%)
2 total products
Financials (FY2025)
Revenue
$2.5B74%
R&D Spend
$1.8B(72%)8%
Net Income
-$882MCash
$3.2BEmployees
12,000Hiring Trend
Actively Hiring
312
Open Roles
+289
Added
-9
Filled/Removed
Based on last 4 crawl cycles